TLP
MDGL icon

Tri Locum Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Tri Locum Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.7M Sell
68,273
-35,015
-34% -$17.9M 4.51% 10
2026
Q1 		$54.1M Buy
103,288
+17,265
+20% +$8.25M 7.59% 7
2025
Q4 		$50.1M Buy
86,023
+18,317
+27% +$9.36M 6.5% 6
2025
Q3 		$31.1M Sell
67,706
-30,059
-31% -$11.2M 7.14% 8
2025
Q2 		$29.6M Buy
97,765
+59,896
+158% +$17.8M 8.98% 2
2025
Q1 		$12.5M Sell
37,869
-9,603
-20% -$3.16M 6.44% 6
2024
Q4 		$14.6M Buy
47,472
+4,185
+10% +$1.18M 3.03% 14
2024
Q3 		$9.19M Sell
43,287
-22,065
-34% -$5.64M 2.2% 16
2024
Q2 		$18.3M Buy
65,352
+11,997
+22% +$2.86M 4.63% 10
2024
Q1 		$14.2M Buy
53,355
+27,831
+109% +$6.56M 4.94% 9
2023
Q4 		$5.91M Sell
25,524
-8,237
-24% -$1.44M 2.7% 15
2023
Q3 		$4.93M Buy
33,761
+7,751
+30% +$1.46M 1.58% 24
2023
Q2 		$6.01M Buy
26,010
+12,165
+88% +$3.29M 2.23% 18
2023
Q1 		$3.35M Sell
13,845
-12,541
-48% -$3.42M 1.02% 29
2022
Q4 		$7.66M Buy
+26,386
New +$2.58M 3.1% 12

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tri Locum Partners's MDGL Position: Q2 2026 in Review

Tri Locum Partners reduced its Madrigal Pharmaceuticals (MDGL) stake by 34% in Q2 2026, selling an estimated $17.9M and leaving 68,273 shares worth $36.7M. The position accounts for 4.51% of the portfolio, ranked #10.

Tri Locum Partners first reported a position in MDGL in Q4 2022 and has held it in 15 quarters since. The position peaked at $54.1M in Q1 2026. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Tri Locum Partners held 68,273 shares of Madrigal Pharmaceuticals worth $36.7M as of Q2 2026.
  • Tri Locum Partners sold 35,015 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $17.9M.
  • Madrigal Pharmaceuticals made up 4.51% of Tri Locum Partners's portfolio in Q2 2026, its #10 holding.
  • Tri Locum Partners first reported a position in Madrigal Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Tri Locum Partners's Madrigal Pharmaceuticals position peaked at $54.1M in Q1 2026.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Tri Locum Partners's 13F filing for Q2 2026, filed 14 Aug 2026.